Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Clinical Infectious Diseases

Volumn 67, Issue 7, 2018, Pages 1010-1017

  Rockstroh, Jürgen K ^a   Lacombe, Karine ^b   Viani, Rolando M ^c,p   Orkin, Chloe ^d   Wyles, David ^e   Luetkemeyer, Anne F ^f   Soto Malave, Ruth ^g   Flisiak, Robert ^h   Bhagani, Sanjay ⁱ   Sherman, Kenneth E ^j   Shimonova, Tatiana ^k   Ruane, Peter ^l   Sasadeusz, Joseph ^m   Slim, Jihad ⁿ   Zhang, Zhenzhen ^c   Samanta, Suvajit ^c   Ng, Teresa I ^c   Gulati, Abhishek ^c,q   Kosloski, Matthew P ^c   Shulman, Nancy S ^c   Trinh, Roger ^c   Sulkowski, Mark ^o   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b INSERM   (France)

^c ABBVIE INC   (United States)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e DENVER HEALTH MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FDDS Management and Engineering   (Puerto Rico)

^h Klinika Chorob Zakaznych I N   (Poland)

ⁱ ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF CINCINNATI   (United States)

^k Moscow Infectious Clinical Hospital 2   (Russian Federation)

^l Ruane Medical and Liver Health Institute   (United States)

^m ROYAL MELBOURNE HOSPITAL   (Australia)

ⁿ ST MICHAEL S MEDICAL CENTER   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Clinical Development Neurocrine Biosciences   (United States)

^q ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

more..

Author keywords

cirrhosis; direct acting antiviral; EXPEDITION 2; hepatitis C; HIV coinfection

Indexed keywords

BILIRUBIN; GLECAPREVIR PLUS PIBRENTASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; GLECAPREVIR AND PIBRENTASVIR; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANTIRETROVIRAL THERAPY; ARTERY DISEASE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC HEPATITIS C; COMPENSATED LIVER CIRRHOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; OBLITERATING ARTERIOPATHY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; UROLITHIASIS; ANIMAL; CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; YOUNG ADULT;

ADULT; ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG COMBINATIONS; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; MALE; PYRROLIDINES; QUINOXALINES; SULFONAMIDES; YOUNG ADULT;

EID: 85049582109     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy220     Document Type: Article

References (39)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44:S6-9.
2. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015;10:297-302.
3. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16:797-808.
4. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48:353-67.
5. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep 2013;10:226-34.
6. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61(suppl 1):i47-58.
7. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011;8:12-22.
8. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018. In press. doi: 10.1016/j.jhep.2018.03.026
9. American Association for the Study of Liver Disease, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C virus. 2017. Available at: http://www.hcvguidelines.org. Accessed 14 June 2017.
10. Townsend K, Petersen T, Gordon LA, et al. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS 2016;30:261-6.
11. Ng T, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 2017;61:pii: e02558-16.
12. Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 2018;62:pii: e01620-17.
13. Kosloski M, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. No clinically relevant drug-drug interactions between methadone or buprenorphine/naloxone and anti-viral combination glecaprevir and pibrentasvir. Antimicrob Agents Chemother 2017;61(10):pii: e00958-17.
14. AbbVie, Inc. Mavyret (glecaprevir/pibrentasvir). Prescribing Information. North Chicago, IL: AbbVie, Inc, 2017.
15. Kosloski MP, Dutta S, Viani RM, et al. Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens (abstract 413). In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections (Seattle, WA). 2017.
16. Oberoi RK, Kosloski MP, Ding B, et al. Interactions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir (abstract 453). In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections (Boston, MA). 2016.
17. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354-69.
18. Puoti M, Foster G, Wang S, et al. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy analysis of genotype 1-6 patients without cirrhosis. J Hepatol 2017;66:S721.
19. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8.
20. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK- 5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319-27.
21. Gilead Sciences. HARVONI (ledipasvir and sofosbuvir) tablets [package insert]. 2015. Available at: https://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/ harvoni/harvoni-pi.pdf. Accessed October 2017.
22. Naggie S, Cooper C, Saag M, et al; ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13.
23. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 2016. Available at: http://apps.who.int/iris/bitstream/10665/206453/1/ WHO-HIV-2016.04-eng.pdf?ua=1. Accessed 10 August 2017.
24. Kowdley KV, Gordon SC, Reddy KR, et al.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
25. Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the german hepatitis C cohort (GECCO-01). Clin Infect Dis 2016;63:1320-4.
26. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 2017;153:113-22.
27. Gilead Sciences International Ltd. VOSEVI (sofosbuvir/velpatasvir/voxilaprevir). Summary of Product Characteristics. 2017. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/004350/ WC500235373.pdf. Accessed 1 October 2017.
28. Gilead Sciences. VOSEVI (sofosbuvir/velpatasvir/voxilaprevir). Prescribing Information. Foster City, CA: Gilead Sciences, 2017.
29. Wyles D, Bräu N, Kottilil S, et al; ASTRAL-5 Investigators. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis 2017;65:6-12.
30. Gane EJ, Poordad F, Zadeikis N, et al. Efficacy, safety, and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Hepatology 2017;66:1-148.
31. Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011;5:406-17.
32. Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. ScientificWorldJournal 2013;2013:704912.
33. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016;43:674-96.
34. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
35. Goicoechea M, Liu S, Best B, et al; California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor- based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8.
36. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.
37. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
38. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-57.
39. Collins LF, Chan A, Zheng J, et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infect Dis 2018;5:ofx264.